News about "Boehringer Ingelheim"

Boehringer Ingelheim Acquires Licence from Kyowa Kirin to Develop Treatment for Autoimmune Diseases

Boehringer Ingelheim has acquired a licence from Kyowa Kirin to develop a small molecule programme targeting autoimmune diseases. The collaboration aims to address significant unmet medical needs and strengthen Boehringer’s pipeline of innovative therapies for patients with inflammatory and immune-related conditions.

Boehringer Ingelheim | 31/10/2025 | By Dineshwori

Boehringer Ingelheim's Zongertinib Shows 77 Percent Response Rate in HER2-Mutant NSCLC

Boehringer Ingelheim presented Phase Ib Beamion LUNG-1 trial data at ESMO 2025, showing that zongertinib achieved a 77 percent Objective Response Rate (ORR) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC.

Boehringer Ingelheim | 24/10/2025 | By Dineshwori

Boehringer Ingelheim's Jascayd Receives US FDA Approval for Oral Treatment Option for Adults with IPF

Jascayd is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung function in IPF patients.

Boehringer Ingelheim | 10/10/2025 | By Dineshwori |  172

Palatin Receives USD 6.5M Milestone Payment Under Retinal Disease Collaboration with Boehringer Ingelheim

Palatin Technologies, the US-based biopharmaceutical company focused on developing medicines that modulate the melanocortin receptor system, announced it has achieved a research milestone under its collaboration with Boehringer Ingelheim, triggering a 6.5 million payment to the company.

Boehringer Ingelheim | 23/09/2025 | By Dineshwori

Boehringer Ingelheim Unveils VETMEDIN Solution

VETMEDIN Solution, now available in the US, provides the same dual mode of action as VETMEDIN® Chewable Tablets.

Boehringer Ingelheim | 25/11/2024 | By Aishwarya |  255

PhoreMost Join Hands with Boehringer Ingelheim

PhoreMost Ltd. has made a multi-project target discovery collaboration with Boehringer Ingelheim.

Boehringer Ingelheim | 04/06/2024 | By Aishwarya |  402

Boehringer Ingelheim Teams Up with Quallent to Expand Access to adalimumab-adbm Injection

Boehringer Ingelheim has signed a deal with Quallent Pharmaceuticals to help expand patient access to citrate-free adalimumab-adbm, Boehringer's biosimilar to Humira (adalimumab), in the US.

Boehringer Ingelheim | 14/05/2024 | By Aishwarya |  567

Boehringer Ingelheim Inks Second Pact with 3T Biosciences to Develop Cancer Immunotherapies

This second research partnership with 3T builds on the successful completion of the initial research partnership announced last year by the two companies.

Boehringer Ingelheim | 05/01/2024 | By Manvi |  478

Boehringer Ingelheim breaks ground on 285M API plant in Germany

Boehringer Ingelheim kicked off construction on a new 285 million euro ($315 million) plant at its German headquarters that will produce active pharmaceutical ingredients and drugs for clinical trials.

Boehringer Ingelheim | 15/06/2023 | By Sudeep Soparkar |  801

Boehringer Ingelheim starts 285M API plant construction in Germany

The Chemical Innovation Plant is expected to begin operating in 2026 at Boehringer’s base in Ingelheim, Germany
<br />

Boehringer Ingelheim | 08/05/2023 | By Sudeep Soparkar |  1050